Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells.

Wolfisberg R, Holmbeck K, Nielsen L, Kapoor A, Rice CM, Bukh J, Scheel TKH.

J Virol. 2019 Sep 12;93(19). pii: e00733-19. doi: 10.1128/JVI.00733-19. Print 2019 Oct 1.

PMID:
31292246
2.

Functional Interplay between RNA Viruses and Non-Coding RNA in Mammals.

Damas ND, Fossat N, Scheel TKH.

Noncoding RNA. 2019 Jan 14;5(1). pii: E7. doi: 10.3390/ncrna5010007. Review.

3.

Correction: miRNA independent hepacivirus variants suggest a strong evolutionary pressure to maintain miR-122 dependence.

Yu Y, Scheel TKH, Luna JM, Chung H, Nishiuchi E, Scull MA, Echeverría N, Ricardo-Lax I, Kapoor A, Lipkin WI, Divers TJ, Antczak DF, Tennant BC, Rice CM.

PLoS Pathog. 2018 Sep 17;14(9):e1007303. doi: 10.1371/journal.ppat.1007303. eCollection 2018 Sep.

4.

New Parvovirus Associated with Serum Hepatitis in Horses after Inoculation of Common Biological Product.

Divers TJ, Tennant BC, Kumar A, McDonough S, Cullen J, Bhuva N, Jain K, Chauhan LS, Scheel TKH, Lipkin WI, Laverack M, Trivedi S, Srinivasa S, Beard L, Rice CM, Burbelo PD, Renshaw RW, Dubovi E, Kapoor A.

Emerg Infect Dis. 2018 Feb;24(2):303-310. doi: 10.3201/eid2402.171031.

5.

Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.

Gottwein JM, Pham LV, Mikkelsen LS, Ghanem L, Ramirez S, Scheel TKH, Carlsen THR, Bukh J.

Gastroenterology. 2018 Apr;154(5):1435-1448. doi: 10.1053/j.gastro.2017.12.015. Epub 2017 Dec 22.

PMID:
29274866
6.

miRNA independent hepacivirus variants suggest a strong evolutionary pressure to maintain miR-122 dependence.

Yu Y, Scheel TKH, Luna JM, Chung H, Nishiuchi E, Scull MA, Echeverría N, Ricardo-Lax I, Kapoor A, Lipkin WI, Divers TJ, Antczak DF, Tennant BC, Rice CM.

PLoS Pathog. 2017 Oct 30;13(10):e1006694. doi: 10.1371/journal.ppat.1006694. eCollection 2017 Oct. Erratum in: PLoS Pathog. 2018 Sep 17;14(9):e1007303.

7.

Viral persistence, liver disease, and host response in a hepatitis C-like virus rat model.

Trivedi S, Murthy S, Sharma H, Hartlage AS, Kumar A, Gadi SV, Simmonds P, Chauhan LV, Scheel TKH, Billerbeck E, Burbelo PD, Rice CM, Lipkin WI, Vandegrift K, Cullen JM, Kapoor A.

Hepatology. 2018 Aug;68(2):435-448. doi: 10.1002/hep.29494. Epub 2018 May 21.

8.

Global mapping of miRNA-target interactions in cattle (Bos taurus).

Scheel TKH, Moore MJ, Luna JM, Nishiuchi E, Fak J, Darnell RB, Rice CM.

Sci Rep. 2017 Aug 15;7(1):8190. doi: 10.1038/s41598-017-07880-8.

9.

Mouse models of acute and chronic hepacivirus infection.

Billerbeck E, Wolfisberg R, Fahnøe U, Xiao JW, Quirk C, Luna JM, Cullen JM, Hartlage AS, Chiriboga L, Ghoshal K, Lipkin WI, Bukh J, Scheel TKH, Kapoor A, Rice CM.

Science. 2017 Jul 14;357(6347):204-208. doi: 10.1126/science.aal1962.

10.

A Broad RNA Virus Survey Reveals Both miRNA Dependence and Functional Sequestration.

Scheel TK, Luna JM, Liniger M, Nishiuchi E, Rozen-Gagnon K, Shlomai A, Auray G, Gerber M, Fak J, Keller I, Bruggmann R, Darnell RB, Ruggli N, Rice CM.

Cell Host Microbe. 2016 Mar 9;19(3):409-23. doi: 10.1016/j.chom.2016.02.007.

11.

miRNA-target chimeras reveal miRNA 3'-end pairing as a major determinant of Argonaute target specificity.

Moore MJ, Scheel TK, Luna JM, Park CY, Fak JJ, Nishiuchi E, Rice CM, Darnell RB.

Nat Commun. 2015 Nov 25;6:8864. doi: 10.1038/ncomms9864.

12.

Hepatitis C virus RNA functionally sequesters miR-122.

Luna JM, Scheel TK, Danino T, Shaw KS, Mele A, Fak JJ, Nishiuchi E, Takacs CN, Catanese MT, de Jong YP, Jacobson IM, Rice CM, Darnell RB.

Cell. 2015 Mar 12;160(6):1099-110. doi: 10.1016/j.cell.2015.02.025.

13.

Characterization of nonprimate hepacivirus and construction of a functional molecular clone.

Scheel TK, Kapoor A, Nishiuchi E, Brock KV, Yu Y, Andrus L, Gu M, Renshaw RW, Dubovi EJ, McDonough SP, Van de Walle GR, Lipkin WI, Divers TJ, Tennant BC, Rice CM.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2192-7. doi: 10.1073/pnas.1500265112. Epub 2015 Feb 2.

14.

Surveying the global virome: identification and characterization of HCV-related animal hepaciviruses.

Scheel TK, Simmonds P, Kapoor A.

Antiviral Res. 2015 Mar;115:83-93. doi: 10.1016/j.antiviral.2014.12.014. Epub 2014 Dec 26. Review.

15.

Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.

Gottwein JM, Jensen SB, Serre SB, Ghanem L, Scheel TK, Jensen TB, Krarup H, Uzcategui N, Mikkelsen LS, Bukh J.

Antimicrob Agents Chemother. 2013 Dec;57(12):6034-49. doi: 10.1128/AAC.01176-13. Epub 2013 Sep 23.

16.

Analysis of hepatitis C virus core/NS5A protein co-localization using novel cell culture systems expressing core-NS2 and NS5A of genotypes 1-7.

Galli A, Scheel TK, Prentoe JC, Mikkelsen LS, Gottwein JM, Bukh J.

J Gen Virol. 2013 Oct;94(Pt 10):2221-35. doi: 10.1099/vir.0.053868-0. Epub 2013 Aug 1.

PMID:
23907394
17.

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.

Scheel TK, Rice CM.

Nat Med. 2013 Jul;19(7):837-49. doi: 10.1038/nm.3248. Review.

18.

Identification of a pegivirus (GB virus-like virus) that infects horses.

Kapoor A, Simmonds P, Cullen JM, Scheel TK, Medina JL, Giannitti F, Nishiuchi E, Brock KV, Burbelo PD, Rice CM, Lipkin WI.

J Virol. 2013 Jun;87(12):7185-90. doi: 10.1128/JVI.00324-13. Epub 2013 Apr 17.

19.

Identification of rodent homologs of hepatitis C virus and pegiviruses.

Kapoor A, Simmonds P, Scheel TK, Hjelle B, Cullen JM, Burbelo PD, Chauhan LV, Duraisamy R, Sanchez Leon M, Jain K, Vandegrift KJ, Calisher CH, Rice CM, Lipkin WI.

MBio. 2013 Apr 9;4(2):e00216-13. doi: 10.1128/mBio.00216-13.

20.

Productive homologous and non-homologous recombination of hepatitis C virus in cell culture.

Scheel TK, Galli A, Li YP, Mikkelsen LS, Gottwein JM, Bukh J.

PLoS Pathog. 2013 Mar;9(3):e1003228. doi: 10.1371/journal.ppat.1003228. Epub 2013 Mar 28.

21.

Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.

Gottwein JM, Jensen SB, Li YP, Ghanem L, Scheel TK, Serre SB, Mikkelsen L, Bukh J.

Antimicrob Agents Chemother. 2013 Mar;57(3):1291-303. doi: 10.1128/AAC.02164-12. Epub 2012 Dec 28.

22.

Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry.

Carlsen TH, Scheel TK, Ramirez S, Foung SK, Bukh J.

J Virol. 2013 Feb;87(3):1385-99. doi: 10.1128/JVI.00684-12. Epub 2012 Nov 14.

23.

Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells.

Saeed M, Scheel TK, Gottwein JM, Marukian S, Dustin LB, Bukh J, Rice CM.

Antimicrob Agents Chemother. 2012 Oct;56(10):5365-73. doi: 10.1128/AAC.01256-12. Epub 2012 Aug 6.

24.

Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems.

Scheel TK, Prentoe J, Carlsen TH, Mikkelsen LS, Gottwein JM, Bukh J.

PLoS Pathog. 2012;8(5):e1002696. doi: 10.1371/journal.ppat.1002696. Epub 2012 May 24.

25.

Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains.

Li YP, Ramirez S, Gottwein JM, Scheel TK, Mikkelsen L, Purcell RH, Bukh J.

Proc Natl Acad Sci U S A. 2012 May 1;109(18):E1101-10. doi: 10.1073/pnas.1203829109. Epub 2012 Mar 30.

26.

Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.

Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J.

Gastroenterology. 2011 Sep;141(3):1067-79. doi: 10.1053/j.gastro.2011.06.004. Epub 2011 Jun 12.

PMID:
21699793
27.

Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A.

Gottwein JM, Jensen TB, Mathiesen CK, Meuleman P, Serre SB, Lademann JB, Ghanem L, Scheel TK, Leroux-Roels G, Bukh J.

J Virol. 2011 Sep;85(17):8913-28. doi: 10.1128/JVI.00049-11. Epub 2011 Jun 22.

28.

MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR.

Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4991-6. doi: 10.1073/pnas.1016606108. Epub 2011 Mar 7.

29.

Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations.

Scheel TK, Gottwein JM, Carlsen TH, Li YP, Jensen TB, Spengler U, Weis N, Bukh J.

J Virol. 2011 Mar;85(6):2891-906. doi: 10.1128/JVI.01605-10. Epub 2010 Dec 22.

30.

Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization.

Prentoe J, Jensen TB, Meuleman P, Serre SB, Scheel TK, Leroux-Roels G, Gottwein JM, Bukh J.

J Virol. 2011 Mar;85(5):2224-34. doi: 10.1128/JVI.01594-10. Epub 2010 Dec 1.

31.

Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.

Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J.

Gastroenterology. 2011 Mar;140(3):1032-42. doi: 10.1053/j.gastro.2010.11.036. Epub 2010 Nov 25.

PMID:
21111742
32.

Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies.

Gottwein JM, Scheel TK, Callendret B, Li YP, Eccleston HB, Engle RE, Govindarajan S, Satterfield W, Purcell RH, Walker CM, Bukh J.

J Virol. 2010 May;84(10):5277-93. doi: 10.1128/JVI.02667-09. Epub 2010 Mar 3.

33.

Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.

Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J.

Hepatology. 2009 Feb;49(2):364-77. doi: 10.1002/hep.22673.

PMID:
19148942
34.

Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection.

Jensen TB, Gottwein JM, Scheel TK, Hoegh AM, Eugen-Olsen J, Bukh J.

J Infect Dis. 2008 Dec 15;198(12):1756-65. doi: 10.1086/593021.

PMID:
19032070
35.

Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.

Scheel TK, Gottwein JM, Jensen TB, Prentoe JC, Hoegh AM, Alter HJ, Eugen-Olsen J, Bukh J.

Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):997-1002. doi: 10.1073/pnas.0711044105. Epub 2008 Jan 14.

36.

Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses.

Gottwein JM, Scheel TK, Hoegh AM, Lademann JB, Eugen-Olsen J, Lisby G, Bukh J.

Gastroenterology. 2007 Nov;133(5):1614-26. Epub 2007 Aug 3.

PMID:
17983807

Supplemental Content

Loading ...
Support Center